September 15, 1997 |
Merck & Co.'s osteoporosis drug, Fosamax, cuts the chances that patients with the bone-thinning disease will be hospitalized, according to findings released Sunday. Women treated with Fosamax, also called alendronate, were 20% less likely to be hospitalized than those taking a placebo, a study said. The study also provides the first evidence that older women who break a bone are more likely to be hospitalized for other reasons, Merck said.
July 14, 1995 |
Americans may soon get their first new treatment for osteoporosis in 20 years. Government scientists declared Thursday that the drug Fosamax increases bone strength and reduces fractures in older women. An advisory committee unanimously recommended the Food and Drug Administration approve the drug, which would become the first non-hormonal treatment for the nation's 20 million osteoporosis patients.
June 13, 2005 |
Even as millions of American women go undiagnosed -- and untreated -- for osteoporosis, a serious condition that can lead to devastating fractures, millions of others are trying to prevent broken bones they might never get. Diagnosed with a milder form of bone loss called osteopenia, which is not truly a disease, they take medication that might not be necessary.
May 9, 2005 |
Bone loss can be insidious, going unnoticed in millions of people -- most of them women -- until spinal damage becomes severe or until a hip fracture starts a spiraling physical decline. Drugs can fight the often-debilitating condition, known as osteoporosis, but they can cause unpleasant side effects. As a result, many people stop taking them, leaving their bones to become ever more brittle and more likely to break.
May 19, 1998 |
A drug used to prevent osteoporosis in older women reduces the risk of breast cancer by as much as 70% without any serious side effects, researchers said Monday at a meeting of the American Society for Clinical Oncology in Los Angeles. The risk reduction produced by the drug, called raloxifene, is about the same as that reported earlier this year for tamoxifen, but the latter drug can increase the risk of endometrial cancer and blood clots.
September 8, 1997 |
A star soccer player, wanting to run a little faster and play a little better, cuts down on her eating and throws up after every meal. Five months later she is hospitalized with medical complications from an eating disorder. A national-class distance runner goes more than 10 years without having a regular menstrual cycle. A college swimmer fractures two ribs while coughing during an asthma attack. Three athletes, three different ailments, but one thing in common--the Female Athlete Triad.
November 9, 1998 |
The first guidelines advising doctors just who should undergo osteoporosis screening and how patients should be treated have been released by a consortium of nongovernment health organizations.
October 15, 2004 |
Men as well as women should do more to prevent osteoporosis, or cases of the bone-wasting disease will mount with the aging population and put a heavy burden on the country's medical system, Surgeon Gen. Richard H. Carmona said Thursday. Osteoporosis "represents a major public health problem," largely because people lack awareness of it and fail to take available steps to combat it, said the surgeon general's first report on the condition.
July 12, 1990 |
A relatively inexpensive and widely available drug can halve the rate of vertebral fractures in women with osteoporosis, according to a study that may offer a new treatment option for some of the 24 million Americans who suffer from brittle bones. The drug, called etidronate, is used to treat Paget's disease, a bone disorder among middle-aged and elderly people. It is not approved for use against osteoporosis, but the manufacturer intends to apply for federal permission.
November 27, 2002 |
U.S. regulators Tuesday approved Eli Lilly and Co.'s new osteoporosis treatment and its new drug for attention deficit hyperactivity disorder. Forteo, a once-a-day injection, is the first U.S.-approved treatment for osteoporosis to stimulate formation of new bone. The Food and Drug Administration cleared Forteo for treating men and post-menopausal women who have the bone-thinning disease and a high risk of fracture.